Advertisement

Pathology & Oncology Research

, Volume 25, Issue 1, pp 369–376 | Cite as

Roles of Fibroblast Activation Protein and Hepatocyte Growth Factor Expressions in Angiogenesis and Metastasis of Gastric Cancer

  • Li-Ming Gao
  • Fang Wang
  • Yue Zheng
  • Zhan-Zhao Fu
  • Lei Zheng
  • Lan-Lan Chen
Original Article

Abstract

This study aims to explore the roles of fibroblast activation protein (FAP) and hepatocyte growth factor (HGF) expressions in the angiogenesis and metastasis of gastric cancer (GC). From May 2012 to December 2015, 110 GC patients who received surgical treatment in the First Hospital of Qinhuangdao were selected. The HGF and FAP expressions in 110 cases of GC, 130 cases of normal gastric mucosa and 115 cases of gastric ulcer were detected by streptavidin-perosidase (SP) method. Venous blood HGF level of GC patients was tested by enzyme-linked immunosorbent assay (ELISA). The micro-vessel number of the patients in the three groups were calculated and analyzed. In GC group, positive expression rates of FAP and HGF protein were 61.8% and 67.3% respectively, which were both higher than those in normal gastric mucosa and gastric ulcer groups. The micro-vessel numbers in patients of the normal gastric mucosa and gastric ulcer groups are far less than that in GC group. FAP, HGF and micro-vessel density (MVD) were significantly correlated with infiltration depth, tumor-node-metastasis (TNM) staging, lymph node metastasis (LNM) and distant metastasis. The results of ELISA showed that serum HGF level was related to tumor size, infiltration degree, TNM staging, LNM and distant metastasis. FAP and HGF expressions in GC were positively correlated with MVD, and the expressions of FAP and HGF in GC were in positive correlation. Our study provided evidence that high FAP and HGF expressions may be positively correlated with the angiogenesis and metastasis of GC.

Keywords

Gastric cancer Fibroblast activation protein Hepatocyte growth factor Angiogenesis Metastasis Microvessel density 

Notes

Acknowledgements

We would like to thank all the people for their technical assistance and valuable advice.

Compliance with ethical standards

Conflict of interest

None.

References

  1. 1.
    Shirahata A, Sakata M, Kitamura Y, Sakuraba K, Yokomizo K, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, Hibi K (2010) MACC 1 as a marker for peritoneal-disseminated gastric carcinoma. Anticancer Res 30:3441–3444Google Scholar
  2. 2.
    Jang BG, Kim WH (2011) Molecular pathology of gastric carcinoma. Pathobiology 78:302–310CrossRefGoogle Scholar
  3. 3.
    Izuishi K, Mori H (2016) Recent strategies for treating stage iv gastric cancer: roles of palliative gastrectomy, chemotherapy, and radiotherapy. J Gastrointestin Liver Dis 25:87–94Google Scholar
  4. 4.
    Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ (2010) Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 11:439–449CrossRefGoogle Scholar
  5. 5.
    Marrelli D, De Stefano A, de Manzoni G, Morgagni P, Di Leo A, Roviello F (2005) Prediction of recurrence after radical surgery for gastric cancer: a scoring system obtained from a prospective multicenter study. Ann Surg 241:247–255CrossRefGoogle Scholar
  6. 6.
    Marrelli D, Pedrazzani C, Neri A, Corso G, DeStefano A, Pinto E, Roviello F (2007) Complications after extended (D2) and superextended (D3) lymphadenectomy for gastric cancer: analysis of potential risk factors. Ann Surg Oncol 14:25–33CrossRefGoogle Scholar
  7. 7.
    Wang RF, Zhang LH, Shan LH, Sun WG, Chai CC, Wu HM, Ibla JC, Wang LF, Liu JR (2013) Effects of the fibroblast activation protein on the invasion and migration of gastric cancer. Exp Mol Pathol 95:350–356CrossRefGoogle Scholar
  8. 8.
    Lordick F (2014) Targeting the HGF/MET pathway in gastric cancer. Lancet Oncol 15:914–916CrossRefGoogle Scholar
  9. 9.
    Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, D'Emidio S, Catalano V, Sisti V, Ligorio C, Andreoni F, Rulli E, Di Oto E, Fiorentini G, Zingaretti C, De Nictolis M, Cappuzzo F, Magnani M (2011) Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 29:4789–4795CrossRefGoogle Scholar
  10. 10.
    Abbas O, Richards JE, Mahalingam M (2010) Fibroblast-activation protein: a single marker that confidently differentiates morpheaform/infiltrative basal cell carcinoma from desmoplastic trichoepithelioma. Mod Pathol 23:1535–1543CrossRefGoogle Scholar
  11. 11.
    El Khoury J, Kurban M, Kibbi AG, Abbas O (2014) Fibroblast-activation protein: valuable marker of cutaneous epithelial malignancy. Arch Dermatol Res 306:359–365CrossRefGoogle Scholar
  12. 12.
    Tchou J, Zhang PJ, Bi Y, Satija C, Marjumdar R, Stephen TL, Lo A, Chen H, Mies C, June CH, Conejo-Garcia J, Pure E (2013) Fibroblast activation protein expression by stromal cells and tumor-associated macrophages in human breast cancer. Hum Pathol 44:2549–2557CrossRefGoogle Scholar
  13. 13.
    Wen Y, Wang CT, Ma TT, Li ZY, Zhou LN, Mu B, Leng F, Shi HS, Li YO, Wei YQ (2010) Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci 101:2325–2332CrossRefGoogle Scholar
  14. 14.
    Yanovitch T, Li YJ, Metlapally R, Abbott D, Viet KN, Young TL (2009) Hepatocyte growth factor and myopia: genetic association analyses in a Caucasian population. Mol Vis 15:1028–1035Google Scholar
  15. 15.
    Cai L, Johnstone BH, Cook TG, Liang Z, Traktuev D, Cornetta K, Ingram DA, Rosen ED, March KL (2007) Suppression of hepatocyte growth factor production impairs the ability of adipose-derived stem cells to promote ischemic tissue revascularization. Stem Cells 25:3234–3243CrossRefGoogle Scholar
  16. 16.
    Nakagami H, Maeda K, Morishita R, Iguchi S, Nishikawa T, Takami Y, Kikuchi Y, Saito Y, Tamai K, Ogihara T, Kaneda Y (2005) Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. Arterioscler Thromb Vasc Biol 25:2542–2547CrossRefGoogle Scholar
  17. 17.
    Zhao L, Yasumoto K, Kawashima A, Nakagawa T, Takeuchi S, Yamada T, Matsumoto K, Yonekura K, Yoshie O, Yano S (2013) Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer. Cancer Sci 104:1640–1646CrossRefGoogle Scholar
  18. 18.
    Wang W, Xu DZ, Li YF, Guan YX, Sun XW, Chen YB, Kesari R, Huang CY, Li W, Zhan YQ, Zhou ZW (2011) Tumor-ratio-metastasis staging system as an alternative to the 7th edition UICC TNM system in gastric cancer after D2 resection--results of a single-institution study of 1343 Chinese patients. Ann Oncol 22:2049–2056CrossRefGoogle Scholar
  19. 19.
    Wroblewski LE, Peek RM Jr, Wilson KT (2010) Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 23:713–739CrossRefGoogle Scholar
  20. 20.
    Lo PC, Chen J, Stefflova K, Warren MS, Navab R, Bandarchi B, Mullins S, Tsao M, Cheng JD, Zheng G (2009) Photodynamic molecular beacon triggered by fibroblast activation protein on cancer-associated fibroblasts for diagnosis and treatment of epithelial cancers. J Med Chem 52:358–368CrossRefGoogle Scholar
  21. 21.
    Inokuchi M, Otsuki S, Fujimori Y, Sato Y, Nakagawa M, Kojima K (2015) Clinical significance of MET in gastric cancer. World J Gastrointest Oncol 7:317–327CrossRefGoogle Scholar
  22. 22.
    Erbersdobler A, Isbarn H, Dix K, Steiner I, Schlomm T, Mirlacher M, Sauter G, Haese A (2010) Prognostic value of microvessel density in prostate cancer: a tissue microarray study. World J Urol 28:687–692CrossRefGoogle Scholar
  23. 23.
    Du JR, Jiang Y, Zhang YM, Fu H (2003) Vascular endothelial growth factor and microvascular density in esophageal and gastric carcinomas. World J Gastroenterol 9:1604–1606CrossRefGoogle Scholar
  24. 24.
    Liu F, Qi L, Liu B, Liu J, Zhang H, Che D, Cao J, Shen J, Geng J, Bi Y, Ye L, Pan B, Yu Y (2015) Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis. PLoS One 10:e0116683CrossRefGoogle Scholar
  25. 25.
    Cai F, Li Z, Wang C, Xian S, Xu G, Peng F, Wei Y, Lu Y (2013) Short hairpin RNA targeting of fibroblast activation protein inhibits tumor growth and improves the tumor microenvironment in a mouse model. BMB Rep 46:252–257CrossRefGoogle Scholar
  26. 26.
    Guo T, Yang J, Yao J, Zhang Y, Da M, Duan Y (2013) Expression of MACC1 and c-Met in human gastric cancer and its clinical significance. Cancer Cell Int 13:121CrossRefGoogle Scholar
  27. 27.
    Noguchi E, Saito N, Kobayashi M, Kameoka S (2015) Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression. Mol Med Rep 11:3423–3431Google Scholar

Copyright information

© Arányi Lajos Foundation 2017

Authors and Affiliations

  • Li-Ming Gao
    • 1
  • Fang Wang
    • 1
  • Yue Zheng
    • 2
  • Zhan-Zhao Fu
    • 1
  • Lei Zheng
    • 1
  • Lan-Lan Chen
    • 1
  1. 1.Department of OncologyFirst Hospital of QinhuangdaoQinhuangdaoPeople’s Republic of China
  2. 2.Department of GastroenterologyFirst Hospital of QinhuangdaoQinhuangdaoPeople’s Republic of China

Personalised recommendations